News

Eli Lilly signs another genetic medicines deal, this time with Genetic Leap, a start-up that applies AI to the discovery of RNA-targeted drugs.
Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.